Rib-X's skin infection drug enters late-stage study

05/17/2013 | Pharmaceutical Business Review Online

Rib-X Pharmaceuticals initiated a late-stage trial to assess the efficacy of a Captisol-enabled IV formulation of delafloxacin in patients with acute bacterial skin and skin structure infections. The trial triggered the payment of a $500,000 milestone fee to partner Ligand Pharmaceuticals.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC
Senior Counsel Commercial
RAI Services Company
Winston Salem, NC
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL